Vanguard Capital Management
TRDA icon

Vanguard Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Vanguard Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.34M Buy
1,269,634
+13,621
+1% +$131K ﹤0.01% 2854
2026
Q1 		$15.9M Buy
+1,256,013
New +$14.4M ﹤0.01% 2473

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's TRDA Position: Q2 2026 in Review

Vanguard Capital Management increased its Entrada Therapeutics (TRDA) stake by 1.1% in Q2 2026, buying an estimated $131K and bringing the position to 1,269,634 shares worth $9.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

Vanguard Capital Management first reported a position in TRDA in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.9M in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Vanguard Capital Management held 1,269,634 shares of Entrada Therapeutics worth $9.34M as of Q2 2026.
  • Vanguard Capital Management bought 13,621 Entrada Therapeutics shares in Q2 2026, an estimated $131K.
  • Entrada Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2854 holding.
  • Vanguard Capital Management first reported a position in Entrada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Entrada Therapeutics position peaked at $15.9M in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.